ArticleDoklady. Biochemistry and biophysics2025
Effects of LYS-ARG-ARG-LYS-PRO-GLY-PRO Peptide, Warfarin, and Acetylsalicylic Acid on Lipid Metabolism in Rats with Metabolic Syndrome.
Article in Doklady. Biochemistry and biophysics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A comparative study of three drugs (KRRKPGP peptide, warfarin and acetylsalicylic acid) with an anticoagulant effect in the body was conducted. The drugs were administered orally in effective doses (peptide and warfarin 100 µg/kg, acetylsalicylic acid 1 mg/kg) for 7 days to laboratory rats with metabolic syndrome induced by a high-calorie diet (HCD). As early as 20 h after the last administration of the drugs, a decrease in the concentration of total cholesterol, low-density lipoprotein cholesterol, and triglycerides and an increase in the concentration of high-density lipoprotein cholesterol and a slowdown in the growth of body weight in rats were detected, which persisted for 7 days after stopping their administration. The greatest hypolipidemic effect was caused by the KRRKPGP peptide.
Indexed as
Identifiers
41083632What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.